Roche Holding OTC Stock Top Insiders
| RHHVF Stock | USD 240.06 2.56 1.06% |
Roche Holding employs about 103.6 K people. The company is managed by 41 executives with a total tenure of roughly 399 years, averaging almost 9.0 years of service per executive, having 2527.15 employees per reported executive. Examination of Roche Holding's management performance can provide insight into the company performance.
| Osamu Nagayama CEO Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai |
| William Anderson CEO Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals |
Roche |
Roche Holding Management Team Effectiveness
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Roche Holding Workforce Comparison
Roche Holding AG is currently regarded as top stock in number of employees category among related companies. The total workforce of Drug Manufacturers—General industry is at this time estimated at about 230,970. Roche Holding totals roughly 103,613 in number of employees claiming about 45% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of 0.19 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.32 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.32. Roche Holding AG Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Roche Holding AG Price Series Summation is a cross summation of Roche Holding price series and its benchmark/peer.
Roche Holding Notable Stakeholders
A Roche Holding stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Roche Holding often face trade-offs trying to please all of them. Roche Holding's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Roche Holding's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Osamu Nagayama | Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | Profile | |
| William Anderson | Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | Profile | |
| PerOlof Attinger | Secretary to the Corporate Executive Committee, Head CEO Office | Profile | |
| Severin Schwan | CEO and Director | Profile | |
| Michael Heuer | Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics | Profile | |
| Andre Hoffmann | Non-Executive Vice Chairman of the Board | Profile | |
| Fritz Gerber | Honorary Chairman of the Board | Profile | |
| Alan Hippe | CFO and IT Officer | Profile | |
| Roland Diggelmann | Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | Profile | |
| Daniel ODay | COO of Pharmaceuticals division | Profile | |
| Beatrice Mauro | Non-Executive Director | Profile | |
| DeAnne Julius | Non-Executive Director | Profile | |
| Claudia Dyckerhoff | Non-Executive Director | Profile | |
| Julie Brown | Non-Executive Director | Profile | |
| Richard Lifton | Non-Executive Director | Profile | |
| Paul Bulcke | Non-Executive Director | Profile | |
| Christoph Franz | Non-Executive Director | Profile | |
| Pius Baschera | Non-Executive Director | Profile | |
| Peter Voser | Non-Executive Director | Profile | |
| Bernard Poussot | Non-Executive Director | Profile | |
| John Bell | Non-Executive Director | Profile | |
| Andreas Oeri | Non-Executive Director | Profile | |
| Anita Hauser | Non-Executive Director | Profile | |
| Barbara Schadler | Head Communications | Profile | |
| Michael Varney | Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | Profile | |
| Bruno Eschli | Head Relations | Profile | |
| Silvia Ayyoubi | Head of Group HR | Profile | |
| Sophie KornowskiBonnet | Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | Profile | |
| Thomas Schinecker | Chief Diagnostics | Profile | |
| Cristina Wilbur | Member of the Executive Committee, Head Group Human Resources | Profile | |
| James Sabry | Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | Profile | |
| Gottlieb Keller | General Counsel and Corporate Secretary | Profile | |
| Urs Jaisli | Chief Compliance Officer | Profile | |
| Claudia Bockstiegel | G Counsel | Profile | |
| Johannes MD | Head Devel | Profile | |
| Karl Mahler | Head of Investor Relations | Profile | |
| John Reed | Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | Profile | |
| Stephan Feldhaus | Member of the Enlarged Corporate Executive Committee, Head Group Communications | Profile | |
| Pascale Schmidt | Chief Officer | Profile | |
| William Pao | Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | Profile | |
| F Hoffmann | IR Contact Officer | Profile |
About Roche Holding Management Performance
The success or failure of an entity such as Roche Holding AG often depends on how effective the management is. Roche Holding management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Roche management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Roche management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company was founded in 1896 and is headquartered in Basel, Switzerland. Roche Hld operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 100920 people.
The data published in Roche Holding's official financial statements usually reflect Roche Holding's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Roche Holding AG. For example, before you start analyzing numbers published by Roche accountants, it's critical to develop an understanding of what Roche Holding's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Roche Holding's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Roche Holding's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Roche Holding's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Roche Holding AG. Please utilize our Beneish M Score to check the likelihood of Roche Holding's management manipulating its earnings.
Roche Holding Workforce Analysis
Traditionally, organizations such as Roche Holding use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Roche Holding within its industry.Roche Holding Manpower Efficiency
Return on Roche Holding Manpower
| Revenue Per Employee | 606.1K | |
| Revenue Per Executive | 1.5B | |
| Net Income Per Employee | 134.4K | |
| Net Income Per Executive | 339.8M | |
| Working Capital Per Employee | 20.8K | |
| Working Capital Per Executive | 52.6M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |